Literature DB >> 19617624

Molecular regulation of matrix extracellular phosphoglycoprotein expression by bone morphogenetic protein-2.

Young-Dan Cho1, Won-Joon Yoon, Kyung-Mi Woo, Jeong-Hwa Baek, Gene Lee, Je-Yoel Cho, Hyun-Mo Ryoo.   

Abstract

Matrix extracellular phosphoglycoprotein (MEPE) is mainly expressed in mineralizing tissues, and its C-terminal proteolytic cleavage product is an acidic-serine-asparate-rich-MEPE-associated motif (ASARM) that is a strong regulator of body phosphate metabolism and mineralization. There is sufficient data supporting a role for MEPE protein function in mineralization, however, little is known about the regulation of MEPE gene expression. As bone morphogenetic protein-2 (BMP-2) is one of the most important signals for calvarial mineralization and MEPE expression is higher in mineralized tissues, we attempted to uncover a regulatory circuit between BMP-2 and MEPE expression. Mepe expression is very low in proliferating MC3T3-E1 cells, but is dramatically increased in the mineralization stage and is strongly stimulated by treatment with BMP-2, even in proliferating cells. Overexpression and knock-down experiments of Smads, Dlx5, and Runx2 indicated that they are indispensable mediators of BMP-2-induced Mepe expression. In contrast, Msx2 showed strong inhibition of Mepe transcription. PHEX is an enzyme that prevents the release of the ASARM motif, a mineralization inhibitor, from the MEPE molecule. Thus, the MEPE/PHEX ratio may be a good indicator of mineralization progression because we found that the mRNA ratio and protein levels were low when osteoblasts were actively differentiating to the mineralization stage and the ratio was high when the cells reached the mineralization stage when it is assumed that osteocytes may protect themselves and make a space to survive from the mineralized matrix by releasing the ASARM motif. Collectively, MEPE expression is bone cell-specific and induced by the BMP-2 signaling pathway. In addition, the MEPE/PHEX ratio of the cell could be a very important barometer indicating the progression of tissue mineralization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19617624      PMCID: PMC2757226          DOI: 10.1074/jbc.M109.008391

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  BMP-2-induced Osterix expression is mediated by Dlx5 but is independent of Runx2.

Authors:  Mi-Hye Lee; Tae-Geon Kwon; Hyo-Sang Park; John M Wozney; Hyun-Mo Ryoo
Journal:  Biochem Biophys Res Commun       Date:  2003-09-26       Impact factor: 3.575

2.  Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone.

Authors:  L Argiro; M Desbarats; F H Glorieux; B Ecarot
Journal:  Genomics       Date:  2001-06-15       Impact factor: 5.736

3.  Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23.

Authors:  K E White; G Carn; B Lorenz-Depiereux; A Benet-Pages; T M Strom; M J Econs
Journal:  Kidney Int       Date:  2001-12       Impact factor: 10.612

4.  Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass.

Authors:  Lori C Gowen; Donna N Petersen; Amy L Mansolf; Hong Qi; Jeffrey L Stock; George T Tkalcevic; Hollis A Simmons; David T Crawford; Kristen L Chidsey-Frink; Hua Zhu Ke; John D McNeish; Thomas A Brown
Journal:  J Biol Chem       Date:  2002-11-05       Impact factor: 5.157

5.  MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia.

Authors:  P S Rowe; P A de Zoysa; R Dong; H R Wang; K E White; M J Econs; C L Oudet
Journal:  Genomics       Date:  2000-07-01       Impact factor: 5.736

6.  The Boston-type craniosynostosis mutation MSX2 (P148H) results in enhanced susceptibility of MSX2 to ubiquitin-dependent degradation.

Authors:  Won-Joon Yoon; Young-Dan Cho; Kwang-Hwi Cho; Kyung-Mi Woo; Jeong-Hwa Baek; Je-Yoel Cho; Gwan-Shik Kim; Hyun-Mo Ryoo
Journal:  J Biol Chem       Date:  2008-09-10       Impact factor: 5.157

7.  Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells.

Authors:  George L Barnes; Amjad Javed; Sylvan M Waller; Mohammad H Kamal; Kerri E Hebert; Mohammad Q Hassan; Akeila Bellahcene; Andre J Van Wijnen; Marian F Young; Jane B Lian; Gary S Stein; Louis C Gerstenfeld
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

8.  BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression.

Authors:  Mi-Hye Lee; Youn-Jeong Kim; Hyun-Jung Kim; Hyun-Dong Park; Ae-Ree Kang; Hee-Moon Kyung; Jae-Hyun Sung; John M Wozney; Hyun-Jung Kim; Hyun-Mo Ryoo
Journal:  J Biol Chem       Date:  2003-06-18       Impact factor: 5.157

Review 9.  FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.

Authors:  L Darryl Quarles
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-07       Impact factor: 4.310

10.  BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop.

Authors:  Georges Rawadi; Béatrice Vayssière; Fred Dunn; Roland Baron; Sergio Roman-Roman
Journal:  J Bone Miner Res       Date:  2003-10       Impact factor: 6.741

View more
  12 in total

1.  Prolyl isomerase Pin1-mediated conformational change and subnuclear focal accumulation of Runx2 are crucial for fibroblast growth factor 2 (FGF2)-induced osteoblast differentiation.

Authors:  Won-Joon Yoon; Young-Dan Cho; Woo-Jin Kim; Han-Sol Bae; Rabia Islam; Kyung-Mi Woo; Jeong-Hwa Baek; Suk-Chul Bae; Hyun-Mo Ryoo
Journal:  J Biol Chem       Date:  2014-02-07       Impact factor: 5.157

2.  Epigenetic modifications and canonical wingless/int-1 class (WNT) signaling enable trans-differentiation of nonosteogenic cells into osteoblasts.

Authors:  Young-Dan Cho; Won-Joon Yoon; Woo-Jin Kim; Kyung-Mi Woo; Jeong-Hwa Baek; Gene Lee; Young Ku; Andre J van Wijnen; Hyun-Mo Ryoo
Journal:  J Biol Chem       Date:  2014-05-27       Impact factor: 5.157

3.  Osteogenic responses to zirconia with hydroxyapatite coating by aerosol deposition.

Authors:  Y Cho; J Hong; H Ryoo; D Kim; J Park; J Han
Journal:  J Dent Res       Date:  2015-01-13       Impact factor: 6.116

4.  Examination of nuclear receptor expression in osteoblasts reveals Rorβ as an important regulator of osteogenesis.

Authors:  Matthew M Roforth; Gang Liu; Sundeep Khosla; David G Monroe
Journal:  J Bone Miner Res       Date:  2012-04       Impact factor: 6.741

5.  Hypoxia inducible factor-1α directly induces the expression of receptor activator of nuclear factor-κB ligand in periodontal ligament fibroblasts.

Authors:  Hyun-Jung Park; Kyung Hwa Baek; Hye-Lim Lee; Arang Kwon; Hyo Rin Hwang; Abdul S Qadir; Kyung Mi Woo; Hyun-Mo Ryoo; Jeong-Hwa Baek
Journal:  Mol Cells       Date:  2011-04-20       Impact factor: 5.034

6.  Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva.

Authors:  Gin-Ah Song; Hyun-Jung Kim; Kyung-Mi Woo; Jeong-Hwa Baek; Gwan-Shik Kim; Jin-Young Choi; Hyun-Mo Ryoo
Journal:  J Biol Chem       Date:  2010-05-12       Impact factor: 5.157

Review 7.  Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.

Authors:  Peter S N Rowe
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2012       Impact factor: 1.807

8.  The canonical BMP signaling pathway plays a crucial part in stimulation of dentin sialophosphoprotein expression by BMP-2.

Authors:  Young-Dan Cho; Won-Joon Yoon; Kyung-Mi Woo; Jeong-Hwa Baek; Joo-Cheol Park; Hyun-Mo Ryoo
Journal:  J Biol Chem       Date:  2010-09-15       Impact factor: 5.157

9.  Phosphatonins: physiological role and pathological changes.

Authors:  Loredana Cavalli; Celestina Mazzotta; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2012-05-29

Review 10.  The chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled.

Authors:  Peter S N Rowe
Journal:  Cell Biochem Funct       Date:  2012-05-09       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.